Table 1
Phase 3 trials incorporating novel agents in the ASCT setting: induction
Mel200 indicates melphalan 200 mg/m2; Dm, dexamethasone maintenance; ORR, overall response rate; VGPR, very good partial response; PR, partial response; IFNm, IFN maintenance; Tm, thalidomide maintenance; VTm, bortezomib-thalidomide maintenance; VBMCP, vincristine, BCNU, melphalan, cyclophosphamide, prednisone; VBAD, vincristine, BCNU, doxorubicin, dexamethasone; V, bortezomib; NR, not reported; Vm, bortezomib maintenance; and TTP, time to progression.
